These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 27706929)

  • 1. Diagnostic accuracy and cost-effectiveness of different strategies to triage women with adnexal masses: a prospective study.
    Piovano E; Cavallero C; Fuso L; Viora E; Ferrero A; Gregori G; Grillo C; Macchi C; Mengozzi G; Mitidieri M; Pagano E; Zola P
    Ultrasound Obstet Gynecol; 2017 Sep; 50(3):395-403. PubMed ID: 27706929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are serum HE4 or ROMA scores useful to experienced examiners for improving characterization of adnexal masses after transvaginal ultrasonography?
    Kaijser J; Van Gorp T; Smet ME; Van Holsbeke C; Sayasneh A; Epstein E; Bourne T; Vergote I; Van Calster B; Timmerman D
    Ultrasound Obstet Gynecol; 2014 Jan; 43(1):89-97. PubMed ID: 23828371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic performance of IOTA SR and O-RADS combined with CA125, HE4, and risk of malignancy algorithm to distinguish benign and malignant adnexal masses.
    Yang Y; Ju H; Huang Y
    Eur J Radiol; 2023 Aug; 165():110926. PubMed ID: 37418798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of applicability of HE4 and ROMA in the preoperative diagnosis of adnexal masses].
    Janas L; Głowacka E; Wilczyński JR; Malinowski A; Nowak M
    Ginekol Pol; 2015 Mar; 86(3):193-7. PubMed ID: 25920309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective external validation of IOTA three-step strategy for characterizing and classifying adnexal masses and retrospective assessment of alternative two-step strategy using simple-rules risk.
    Hidalgo JJ; Ros F; Aubá M; Errasti T; Olartecoechea B; Ruiz-Zambrana Á; Alcázar JL
    Ultrasound Obstet Gynecol; 2019 May; 53(5):693-700. PubMed ID: 30353585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the predictive performance of risk of malignancy indexes 1-4, HE4 and risk of malignancy algorithm in the triage of adnexal masses.
    Hada A; Han LP; Chen Y; Hu QH; Yuan Y; Liu L
    J Ovarian Res; 2020 Apr; 13(1):46. PubMed ID: 32334618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses.
    Van Gorp T; Veldman J; Van Calster B; Cadron I; Leunen K; Amant F; Timmerman D; Vergote I
    Eur J Cancer; 2012 Jul; 48(11):1649-56. PubMed ID: 22226481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses.
    Terlikowska KM; Dobrzycka B; Witkowska AM; Mackowiak-Matejczyk B; Sledziewski TK; Kinalski M; Terlikowski SJ
    J Ovarian Res; 2016 Jul; 9(1):43. PubMed ID: 27436085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
    Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
    Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of CA 125 alone and risk of ovarian malignancy algorithm (ROMA) in patients with adnexal mass: A multicenter study.
    Choi HJ; Lee YY; Sohn I; Kim YM; Kim JW; Kang S; Kim BG
    Curr Probl Cancer; 2020 Apr; 44(2):100508. PubMed ID: 31708114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy of IOTA Simple Rules, IOTA ADNEX Model, RMI, and Subjective Assessment for Preoperative Adnexal Mass Evaluation: The Experience of a Tertiary Care Referral Hospital.
    Vilendecic Z; Radojevic M; Stefanovic K; Dotlic J; Likic Ladjevic I; Dugalic S; Stefanovic A
    Gynecol Obstet Invest; 2023; 88(2):116-122. PubMed ID: 36716716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. External validation of IOTA simple descriptors and simple rules for classifying adnexal masses.
    Alcázar JL; Pascual MA; Graupera B; Aubá M; Errasti T; Olartecoechea B; Ruiz-Zambrana A; Hereter L; Ajossa S; Guerriero S
    Ultrasound Obstet Gynecol; 2016 Sep; 48(3):397-402. PubMed ID: 26748432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discriminative value of CA-125, HE4, Risk of Malignancy Index II (RMI-II) and Risk of Malignancy Algorithm (ROMA) in the differential diagnosis of pelvic masses: conclusions from a referral Centre in Portugal.
    Melo Â; Veríssimo R; Farinha M; Martins NN; Martins FN
    J Obstet Gynaecol; 2018 Nov; 38(8):1140-1145. PubMed ID: 29884096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultrasound examination, MRI, or ROMA for discriminating between inconclusive adnexal masses as determined by IOTA Simple Rules: a prospective study.
    Chacon E; Arraiza M; Manzour N; Benito A; Mínguez JÁ; Vázquez-Vicente D; Castellanos T; Chiva L; Alcazar JL
    Int J Gynecol Cancer; 2023 Jun; 33(6):951-956. PubMed ID: 37055169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
    Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
    Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison between an ultrasound based prediction model (LR2) and the risk of ovarian malignancy algorithm (ROMA) to assess the risk of malignancy in women with an adnexal mass.
    Kaijser J; Van Gorp T; Van Hoorde K; Van Holsbeke C; Sayasneh A; Vergote I; Bourne T; Timmerman D; Van Calster B
    Gynecol Oncol; 2013 May; 129(2):377-83. PubMed ID: 23360924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic performance of IOTA simple rules for adnexal masses classification: a comparison between two centers with different ovarian cancer prevalence.
    Ruiz de Gauna B; Rodriguez D; Olartecoechea B; Aubá M; Jurado M; Gómez Roig MD; Alcázar JL
    Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():10-4. PubMed ID: 26066289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative multimodal strategies for risk assessment of adnexal masses: analysis of 1362 cases in a gynecologic cancer center.
    Radosa MP; Camara O; Vorwergk J; Diebolder H; Winzer H; Mothes A; Gajda M; Runnebaum IB
    Int J Gynecol Cancer; 2011 Aug; 21(6):1056-62. PubMed ID: 21633301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women.
    Holcomb K; Vucetic Z; Miller MC; Knapp RC
    Am J Obstet Gynecol; 2011 Oct; 205(4):358.e1-6. PubMed ID: 21722869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of IOTA Simple Rules Risks, ADNEX Model, Subjective Assessment Compared to CA125 and HE4 with ROMA Algorithm in Discriminating between Benign, Borderline and Stage I Malignant Adnexal Lesions.
    Czekierdowski A; Stachowicz N; Smolen A; Łoziński T; Guzik P; Kluz T
    Diagnostics (Basel); 2023 Feb; 13(5):. PubMed ID: 36900029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.